Show simple item record

dc.contributor.authorConteduca, V
dc.contributor.authorMosca, A
dc.contributor.authorBrighi, N
dc.contributor.authorde Giorgi, U
dc.contributor.authorRescigno, P
dc.date.accessioned2021-04-09T14:00:29Z
dc.date.available2021-04-09T14:00:29Z
dc.date.issued2021-01-19
dc.identifier.citationCells, 2021, 10 (1)
dc.identifier.issn2073-4409
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4512
dc.identifier.eissn2073-4409
dc.identifier.doi10.3390/cells10010193
dc.description.abstractProstate cancer is one of the most frequent cancers in men and is a common cause of cancer-related death. Despite significant progress in the diagnosis and treatment of this tumor, patients who relapse after radical treatments inevitably develop metastatic disease. Patient stratification is therefore key in this type of cancer, and there is an urgent need for prognostic biomarkers that can define patients' risk of cancer-related death. In the last 10 years, multiple prognostic factors have been identified and studied. Here, we review the literature available and discuss the most common aberrant genomic pathways in metastatic castration-resistant prostate cancer shown to have a prognostic relevance in this setting.
dc.formatElectronic
dc.languageeng
dc.language.isoeng
dc.publisherMDPI
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleNew Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer.
dc.typeJournal Article
dcterms.dateAccepted2021-01-13
rioxxterms.versionVoR
rioxxterms.versionofrecord10.3390/cells10010193
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-01-19
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCells
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished
pubs.volume10
pubs.embargo.termsNot known
icr.researchteamProstate Cancer Targeted Therapy Group
icr.researchteamProstate Cancer Targeted Therapy Group
dc.contributor.icrauthorRescigno, Pasquale


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0